Evidence map›Paper›PMID 42304195›Full record

ArticleBMC bioinformatics2026

MuSA: a Nextflow pipeline for deep, reproducible annotation and clinical ranking of genomic variants.

D Scognamiglio, E Bonetti, A Moroni, L Sangiorgi, E Pedrini

Abstract read
In one paragraph

Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

D Scognamiglio *Alma Mater Studiorum, Università di Bologna, Bologna, Italy. davide.scognamiglio2@unibo.it.
E Bonetti *Department of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, 40136, Bologna, Italy.
A MoroniDepartment of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, 40136, Bologna, Italy.
L SangiorgiDepartment of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, 40136, Bologna, Italy.
E PedriniDepartment of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, 40136, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccurate clinical interpretation of genetic variants requires integration of functional predictions, evolutionary constraint, population allele frequencies, and clinical evidence from heterogeneous resources. Conventional workflows based on standalone tools such as ensembl variant effect predictor (VEP) and ANNOVAR require complex manual configuration of plugins and databases, generate verbose transcript-level outputs unsuitable for clinical review, and rely on ad hoc scripts for format conversion and prioritization. These limitations hinder reproducibility and scalability, making data interpretation a major bottleneck in genomic medicine.

resultsWe present MuSA (Multi-Source variant Annotation), an nf-core-compliant Nextflow pipeline that automates germline variant annotation from resource setup to clinical interpretation. MuSA supports both a streamlined basic mode for diagnostic workflows and an extended deep-annotation mode for comprehensive analyses. The pipeline integrates Ensembl VEP with 22 curated plugins (including AlphaMissense, CADD, SpliceAI, and Enformer), ANNOVAR, a standalone pre-configured dbNSFP distribution, the RENOVO pathogenicity predictor, and automated ACMG/AMP classification via GeneBe and InterVar. MuSA standardizes input VCFs, executes parallel annotation branches in a fully containerized workflow, and consolidates results into richly annotated mutation annotation format (MAF) files (up to 920 columns per variant), alongside interactive HTML reports tailored for clinical review with HPO-matched gene panels. Benchmarked on a WES-like dataset of 22,705 variants derived from the public GIAB NA12878/HG001 GRCh38 benchmark VCF, MuSA completes full extended-mode annotation in approximately 20 min on a 64-core server. Systematic comparison with nf-core/sarek and nf-core/variantprioritization demonstrates that MuSA uniquely combines automated resource management with YAML-based version tracking and SHA-256 integrity verification, native dbNSFP integration, RENOVO-based VUS prioritization, HPO-driven gene panel filtering, and a clinically oriented interactive HTML report; those features are mostly absent in existing nf-core annotation pipelines. Containerization through Docker/Singularity and predefined execution profiles support reproducible deployment across workstations, HPC clusters, and cloud environments.

conclusionsMuSA provides an end-to-end framework for clinically oriented germline variant annotation and prioritization, addressing key limitations of manual and general-purpose workflows. Its dual-output design bridges research (machine-readable MAF files compatible with downstream tools such as maftools) and clinical diagnostics (interpretation-ready HTML reports), supporting reproducible and standardized variant interpretation across teams. Current limitations include restriction to germline small variants on hg38, a substantial storage footprint (up to 223.5 GB for extended mode), and dependence on external APIs for ACMG/AMP classification and phenotype-driven filtering. The RENOVO-based VUS prioritization module is experimental and requires expert review before clinical interpretation.

Indexed as

Computational BiologyGenetic VariationGenomicsMolecular Sequence AnnotationSoftwareDatabases, GeneticHumansReproducibility of ResultsACMG/AMP guidelinesClinical genomicsNextflow pipelineNf-core communityVariant annotation

Identifiers

PMID42304195
PMCPMC13508343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.